
	Three Months Ended
(in thousands)	September 25, 2026		September 26, 2025
Balance at beginning of period	$	89,103	$	—
Adjustments related to non-marketable equity securities
Net additions	—		—
Unrealized gains (losses)	(21,456)		—
Impairments	—		—
Balance at end of period	$	67,647	$	—

On March 25, 2026, the Company entered into a share purchase agreement to acquire a 13.8% equity interest in Raytek Semiconductor, Inc. (“Raytek”) for a total purchase price of approximately New Taiwan Dollar (“NT$”) 1.02 billion ($32.4 million). The Company evaluated the investment under ASC 323, Investments—Equity Method and Joint Ventures, and determined that the Company does not have significant influence over Raytek’s operating and financial policies. Accordingly, the investment is not accounted for under the equity method and instead falls within the scope of ASC 321, Investments—Equity Securities.

The Company accounts for this investment using the measurement alternative under ASC 321 because the investment does not have a readily determinable fair value. Under the measurement alternative, the investment is measured at cost, less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer.

In May 2026, Raytek’s shares began trading on the Taipei Exchange Emerging Stock Board (“ESB”). The shares held by the Company are subject to restrictions and are not currently listed or publicly tradable on the ESB. The Company determined that trading in Raytek’s publicly traded shares represented an observable price change for purposes of applying the ASC 321 measurement alternative. Accordingly, as of September 25, 2026, the Company remeasured its investment based on the observable ESB market price, adjusted to reflect differences between the publicly traded shares and the Company's shares, including a discount for the lack of marketability associated with the Company's restricted shares. As a result of the remeasurement, the Company recognized an unrealized loss of $21.5 million in other income (expense), net, for the three months ended September 25, 2026 and decreased the carrying amount of the investment to $67.6 million as of September 25, 2026. As of June 26, 2026, the carrying amount of the investment was $89.1 million.